Other ongoing trials include tafasitamab + lenalidomide combination in patients with relapsed/refractory DLBCL (firmMIND) [127], tafasitamab + lenalidomide + R-CHOP vs. R-CHOP for newly diagnosed DLBCL (frontMIND) [128]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.